ClinicalTrials.gg
CompletedNCT03525834Updated Sep 9, 2021Results posted

Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.

A Phase 4 interventional study of Everolimus in Renal Angiomyolipoma, sponsored by Novartis Pharmaceuticals. Completed at 5 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-09.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing everolimus in Tuberous Sclerosis — none open to participants now, 1 under way, 1 of them phase 3. Everolimus · Tuberous Sclerosis.

Enrollment
8th of 17
40 · median 36
Started
2018
the only one that year
Phase 4
2 of 17
none open now
Registered
16th of 17
by date
Lead sponsor
6 of 17
Novartis Pharmaceuticals

Among the 17 studies testing everolimus in Tuberous Sclerosis, this one is the 8th largest by enrollment, is the only one that started in 2018, is one of 2 in phase 4, and was the 16th registered.

Tuberous Sclerosis

115 studies on the registry are indexed under Tuberous Sclerosis; 27 are open to participants now.

Browse Tuberous Sclerosis studies →

Open to participants now

None of the 17 studies testing everolimus in Tuberous Sclerosis is open now. The open studies under Tuberous Sclerosis, anywhere →

About everolimus

Everolimus: first FDA approval 2009 (AFINITOR), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 21 Tuberous Sclerosis studies recruiting now, 10 (48%) set no upper age limit and 8 (38%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing everolimus in Tuberous Sclerosis as a file.
02

Study summary

The purpose of this study was to assess the safety and efficacy of everolimus (Afinitor®) in Chinese patients with renal angiomyolipoma (AML) associated with tuberous sclerosis complex (TSC).

Read the detailed description

This was an open label, single arm, multi-center, Phase IV Post-Approval Commitment (PAC) study with once daily oral dose of 10 mg everolimus in participants with renal AML associated with TSC. There were three separate phases in this study: a Screening phase, an Open-label treatment phase where participants received everolimus for 48 weeks or until disease progression, and a Treatment discontinuation follow-up phase for patients who discontinue study drug for reasons other than disease progression. Every participant had an End of Treatment visit within 28 days after last dose and a safety follow-up visit 30 days after last dose.

03

Conditions studied

  • Renal Angiomyolipoma

Keywords

  • TSC
  • tuberous sclerosis complex
  • AML
  • afinitor
  • everolimus
  • RAD001
  • mTOR
  • kidney
  • lymphangioleiomyomatosis
  • renal angiomyolipoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Eligible for treatment with everolimus as per the locally approved label.
  • Presence of at least one AML ≥ 3 cm in its longest diameter using CT or MRI.

Exclusion criteria

Exclusion Criteria:

  • AML related bleeding or embolization during the 6 months prior to enrollment.
  • History of myocardial infarction, angina or stroke related to atherosclerosis.
  • Impaired lung function.
  • Significant hematological or hepatic abnormality.
  • Any severe and/or uncontrolled medical conditions.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Everolimus

    Participants targeted to receive Everolimus tablets 10 mg orally once daily for 48 weeks.

    Drug: Everolimus

Interventions

  • Everolimus 2.5 mg and 5 mg tablets with dosage regimen of 10 mg orally once daily.

    Also known as: RAD001, Afinitor®

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Percentage of participants with AEs and SAEs including significant changes from baseline in vital signs, electrocardiograms and laboratory parameters (laboratory assessments included hematology, biochemistry, coagulation and urinalysis) qualifying and reported as AEs. The percentage of participants in each category is reported in the table.

    Time frame: From the start of treatment to 30 days after end of treatment, assessed up to maximum duration of 52 weeks

Secondary outcomes

  1. Percentage of Participants With Best Overall Response (BOR) Status of Angiomyolipoma (AML) Response During Maximum Treatment Duration of 48 Weeks

    BOR status is the best status recorded from start of treatment until disease progression. AML response status: reduction in AML volume of at least 50% relative to screening AML. In addition, AML response have to satisfy: no new AML ≥ 1 cm in longest diameter are identified, neither kidney increases in volume by more than 20% from nadir (where nadir is the lowest kidney volume at the screening), the participant does not have any angiomyolipoma-related bleeding of grade equal or over 2 (as defined by NCI CTCAE, version 4.03). Up to five of the largest measurable lesions (≥ 1 cm in longest diameter) in each kidney were measured at screening via Magnetic Resonance Imaging/Computed tomography (MRI/CT) and were defined as screening AML. The sum of the volumes of these individual lesions was defined as AML volume and it was measured at each assessment during the trial. Increases in the AML volume were evidence of worsening AML, decreases were evidence of clinical response.

    Time frame: Baseline, 48 weeks

  2. Percentage of Participants With Best Overall Response Status of Angiomyolipoma (AML) Progression During Maximum Treatment Duration of 48 Weeks

    AML progression status is defined as one or more of the following: an increase from nadir of 25% or more in AML volume to a value greater than screening AML (where nadir is the lowest AML volume obtained for the participant previously in the trial), the appearance of a new AML ≥ 1.0 cm in longest diameter, an increase from nadir of 20% or more in the volume of either kidney to a value greater than screening (where nadir is the lowest kidney volume obtained for the participant previously in the trial), angiomyolipoma-related bleeding grade ≥2 (as defined by NCI CTCAE, version 4.03). Up to five of the largest measurable lesions (≥ 1 cm in longest diameter) in each kidney were measured at screening via Magnetic Resonance Imaging/Computed tomography (MRI/CT) and were defined as screening AML. The sum of the volumes of these individual lesions was defined as AML volume and it was measured at each assessment during the trial. Increases in the AML volume were evidence of worsening AML.

    Time frame: Baseline, 48 weeks

  3. Percentage of Participants With Severe Renal Impairment

    Renal impairment is defined as calculated Creatinine Clearance (CrCl) \< 30 mL/min. CrCl was measured at baseline and at four other time points; only the baseline and the worst post-baseline value for every participant were counted (lowest value for CrCl). Creatinine clearance was estimated using the Cockcroft-Gault formula: creatinine clearance (mL/minute) = urine creatinine concentration (mL/dL) x volume of urine (mL/24 hour) / plasma creatinine concentration (mg/dL) x 1440 minute/24 hour

    Time frame: Baseline, 48 weeks

  4. Percentage of Participants With NCI CTCA Grade 3/4 Serum Creatinine

    NCI CTCAE grade 3/4 serum creatinine is defined as \> 3.0 x upper limits of normal (ULN). Serum creatinine was measured at baseline and at four other time points; only the worst post-baseline value for every participant was counted (highest value for serum creatinine).

    Time frame: Baseline, 48 weeks

07

Results

Posted Sep 9, 2021

Participant flow

All participants were enrolled in 5 different sites in China.

Participant flow — Overall Study
MilestoneEverolimus
Started40
Completed39
Not completed1
Withdrew: Progressive disease1

Outcome measures

PrimaryPercentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

Percentage of participants with AEs and SAEs including significant changes from baseline in vital signs, electrocardiograms and laboratory parameters (laboratory assessments included hematology, biochemistry, coagulation and urinalysis) qualifying and reported as AEs. The percentage of participants in each category is reported in the table.

Time frame:
From the start of treatment to 30 days after end of treatment, assessed up to maximum duration of 52 weeks
Reported as:
Count of participants · Participants
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsEverolimus
AEs40
Treatment-related AEs39
SAEs6
Treatment-related SAEs2
SecondaryPercentage of Participants With Best Overall Response (BOR) Status of Angiomyolipoma (AML) Response During Maximum Treatment Duration of 48 Weeks

BOR status is the best status recorded from start of treatment until disease progression. AML response status: reduction in AML volume of at least 50% relative to screening AML. In addition, AML response have to satisfy: no new AML ≥ 1 cm in longest diameter are identified, neither kidney increases in volume by more than 20% from nadir (where nadir is the lowest kidney volume at the screening), the participant does not have any angiomyolipoma-related bleeding of grade equal or over 2 (as defined by NCI CTCAE, version 4.03). Up to five of the largest measurable lesions (≥ 1 cm in longest diameter) in each kidney were measured at screening via Magnetic Resonance Imaging/Computed tomography (MRI/CT) and were defined as screening AML. The sum of the volumes of these individual lesions was defined as AML volume and it was measured at each assessment during the trial. Increases in the AML volume were evidence of worsening AML, decreases were evidence of clinical response.

Time frame:
Baseline, 48 weeks
Reported as:
Count of participants · Participants
Percentage of Participants With Best Overall Response (BOR) Status of Angiomyolipoma (AML) Response During Maximum Treatment Duration of 48 Weeks
ParticipantsEverolimus
Percentage of Participants With Best Overall Response (BOR) Status of Angiomyolipoma (AML) Response During Maximum Treatment Duration of 48 Weeks28
SecondaryPercentage of Participants With Best Overall Response Status of Angiomyolipoma (AML) Progression During Maximum Treatment Duration of 48 Weeks

AML progression status is defined as one or more of the following: an increase from nadir of 25% or more in AML volume to a value greater than screening AML (where nadir is the lowest AML volume obtained for the participant previously in the trial), the appearance of a new AML ≥ 1.0 cm in longest diameter, an increase from nadir of 20% or more in the volume of either kidney to a value greater than screening (where nadir is the lowest kidney volume obtained for the participant previously in the trial), angiomyolipoma-related bleeding grade ≥2 (as defined by NCI CTCAE, version 4.03). Up to five of the largest measurable lesions (≥ 1 cm in longest diameter) in each kidney were measured at screening via Magnetic Resonance Imaging/Computed tomography (MRI/CT) and were defined as screening AML. The sum of the volumes of these individual lesions was defined as AML volume and it was measured at each assessment during the trial. Increases in the AML volume were evidence of worsening AML.

Time frame:
Baseline, 48 weeks
Reported as:
Count of participants · Participants
Percentage of Participants With Best Overall Response Status of Angiomyolipoma (AML) Progression During Maximum Treatment Duration of 48 Weeks
ParticipantsEverolimus
Percentage of Participants With Best Overall Response Status of Angiomyolipoma (AML) Progression During Maximum Treatment Duration of 48 Weeks1
SecondaryPercentage of Participants With Severe Renal Impairment

Renal impairment is defined as calculated Creatinine Clearance (CrCl) \< 30 mL/min. CrCl was measured at baseline and at four other time points; only the baseline and the worst post-baseline value for every participant were counted (lowest value for CrCl). Creatinine clearance was estimated using the Cockcroft-Gault formula: creatinine clearance (mL/minute) = urine creatinine concentration (mL/dL) x volume of urine (mL/24 hour) / plasma creatinine concentration (mg/dL) x 1440 minute/24 hour

Time frame:
Baseline, 48 weeks
Reported as:
Count of participants · Participants
Percentage of Participants With Severe Renal Impairment
ParticipantsEverolimus
Baseline0
Post-baseline, 48 weeks1
SecondaryPercentage of Participants With NCI CTCA Grade 3/4 Serum Creatinine

NCI CTCAE grade 3/4 serum creatinine is defined as \> 3.0 x upper limits of normal (ULN). Serum creatinine was measured at baseline and at four other time points; only the worst post-baseline value for every participant was counted (highest value for serum creatinine).

Time frame:
Baseline, 48 weeks
Reported as:
Count of participants · Participants
Percentage of Participants With NCI CTCA Grade 3/4 Serum Creatinine
ParticipantsEverolimus
Baseline0
Post-baseline, 48 weeks0

Adverse events

Collected over Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 52 weeks.. Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Everolimus0/40 (0%)6/40 (15%)39/40 (97.5%)
Most frequent serious events
Most frequent serious events
EventEverolimus
HaemorrhoidsGastrointestinal disorders1/40
StomatitisGastrointestinal disorders1/40
GastroenteritisInfections and infestations1/40
PneumoniaInfections and infestations1/40
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/40
Transient psychosisPsychiatric disorders1/40
Most frequent other events
Showing 10 of 44
Most frequent other events
EventEverolimus
StomatitisGastrointestinal disorders18/40
Mouth ulcerationGastrointestinal disorders15/40
Blood triglycerides increasedInvestigations11/40
Blood cholesterol increasedInvestigations10/40
HypercholesterolaemiaMetabolism and nutrition disorders10/40
HypertriglyceridaemiaMetabolism and nutrition disorders10/40
AnaemiaBlood and lymphatic system disorders8/40
Blood lactate dehydrogenase increasedInvestigations8/40
Protein urine presentInvestigations8/40
Alanine aminotransferase increasedInvestigations7/40

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Everolimus
Mean33.7 ± 10.80
Sex: Female, Male
Sex: Female, Male(Participants)Everolimus
Female26
Male14
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Everolimus
Race — Asian, Chinese40
08

Study locations

5 sites
  • Novartis Investigative Site
    Wuhan, Hubei 430030, China
  • Novartis Investigative Site
    Shanghai, Shanghai 200032, China
  • Novartis Investigative Site
    Chengdu, Sichuan 610041, China
  • Novartis Investigative Site
    Beijing, 100028, China
  • Novartis Investigative Site
    Beijing, 100730, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on https://www.clinicalstudydatarequest.com/.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2018 to primary completion in Sep 2020, 22 months.

Results were first posted in Sep 2021, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2018
First posted
May 16, 2018
StartActual
Nov 9, 2018
Primary completionActual
Sep 25, 2020
CompletionActual
Sep 25, 2020
Results first posted
Sep 9, 2021
Last update
Sep 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03525834
Responsible party
Sponsor
First posted
May 16, 2018
Start date
Nov 9, 2018
Primary completion
Sep 25, 2020
Completion
Sep 25, 2020
Results posted
Sep 9, 2021
Last update
Sep 9, 2021

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Everolimus

Start the discussion